API | celiprolol

celiprolol Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Celiprolol is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist. ^Wikipedia

Chemistry

SMILES: CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(=O)C
InChIKey: JOATXPAWOHTVSZ-UHFFFAOYSA-N
Mol. Mass: 379.5
ALogP: 2.89 Partition coefficient
ChEMBL Molecules:

celiprolol

celiprolol hydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Beta-1 adrenergic receptor (Homo sapiens) ^UniProt
- Beta-2 adrenergic receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

celectol | celiprolol | celiprolol hcl | celiprolol hydrochloride | celiprolol monohydrochloride | dl-celiprolol | rs)-n'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-n,n-diethylurea | selecor | selectol

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Antihypertensive Agents

Experimental Indications - Clinical Trial Phases 1-4 (4)

Chromosome Aberrations (Phase 4)

Ehlers-Danlos Syndrome (Phase 4)

Postoperative Complications (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue